Preclinical safety of solid lipid nanoparticles and nanostructured lipid carriers: Current evidence from in vitro and in vivo evaluation

• Type: Article in International Scientific Journal
• Date: 2016

Authors

Doktorovová, S (Author) Other; Kova¿evi¿, AB (Author) Other; Garcia, ML (Author) Other; Souto, EB (Author) Other

Journal

Title: European Journal of Pharmaceutics and Biopharmaceutics

Vol. 108

Pages: 235-252

ISSN: 0939-6411

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 46 Citations

Scopus - 124 Citations

Other information

Authenticus ID: P-00M-6JS

DOI: 10.1016/j.ejpb.2016.08.001

Abstract (EN): Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) were designed as exceptionally safe colloidal carriers for the delivery of poorly soluble drugs. SLN/NLC have the particularity of being composed of excipientsalready approved for use in medicines for human use, which offers a great advantage over any other nanoparticulate system developed from novel materials. Despite this fact, any use of excipients in new route of administration or in new dosage form requires evidence of safety. After 25 years of research on SLN and NLC, enough evidence on their preclinical safety has been published. In the present work, published data on in vitro and in vivo compatibility of SLN/NLC have been surveyed, in order to provide evidence of high biocompatibility distinguished by intended administration route. We also identified critical factors and possible weak points in SLN/NLC formulations, such as the effect of surfactants on the cell viability in vitro, which should be considered for further development. © 2016 Elsevier B.V.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 18